Disease relevance of Detapac

• Acute deterioration of myasthenia gravis after intravenous administration of gadolinium-DTPA [1].
• A multi-centre longitudinal study comparing the sensitivity of monthly MRI after standard and triple dose gadolinium-DTPA for monitoring disease activity in multiple sclerosis. Implications for phase II clinical trials [2].
• Duration and selectivity of blood-brain barrier breakdown in chronic relapsing experimental allergic encephalomyelitis studied by gadolinium-DTPA and protein markers [3].
• Gadolinium-diethylenetriamine pentaacetic acid-enhanced MRI was performed in 21 patients with knee synovitis [4].
• Gadolinium-DTPA (Gd-DTPA) enhancement seen with magnetic resonance imaging in chronic relapsing experimental allergic encephalomyelitis (CREAE) corresponded with sites of blood-brain barrier breakdown judged by traditional markers in areas of inflammatory demyelination [3].

Psychiatry related information on Detapac

• Experimental acute pancreatitis: MR relaxation time studies using gadolinium-DTPA [5].
• Gadolinium-DTPA-enhanced magnetic resonance imaging (MRI) of the posterior cranial fossa portrayed an intracanalicular tumour image (2-3 mm), and the pure tone average (PTA) and speech discrimination score (SDS) values were 65 dB and 60 per cent, respectively [6].

High impact information on Detapac

• Magnetic resonance imaging with gadolinium-DTPA for detecting cardiac transplant rejection in rats [7].
• The mean reduction in tumor initial area under the gadolinium-diethylenetriamine pentaacetic acid concentration-time curve (AUC) was 33% and 18%, respectively, at these times [8].
• Every 4 weeks for 3 months, 10 patients with relapsing-remitting MS were scanned with a T1-weighted sequence, 20 minutes after injection with 0.3 mmol/kg gadolinium-DTPA (Gd-DTPA) [9].
• Disrupture of the blood-brain barrier was assessed also with magnetic resonance imaging after administration of gadolinium-diethylenetriamine pentaacetic acid [10].
• We studied 24 elderly stroke patients and 27 control subjects with conventional MRI which included T2-weighted FLAIR coronal slices through whole brain and gadolinium-DTPA (0.2 mmol/kg)-based perfusion MRI (pMRI) with echo planar imaging [11].

Chemical compound and disease context of Detapac

• In controls and patients, MPR (hyperemic/resting perfusion) and Endo/Epi ratio were determined with MRPI after injection of gadolinium-diethylenetriamine pentaacetic acid at rest and during hyperemia (intravenous adenosine) [12].
• Diagnosis of cardiac sarcoidosis and evaluation of the effects of steroid therapy by gadolinium-DTPA-enhanced magnetic resonance imaging [13].
• Quantitative MRI changes in gadolinium-DTPA enhancement after high-dose intravenous methylprednisolone in multiple sclerosis [14].
• The enhancement properties of gadobutrol (40 and 80 mumol/kg body weight, 550 daltons), gadolinium-DTPA-polylysine (20 mumol/kg body weight, 53,000 daltons) and gadolinium-DTPA-cascade-polymer (20 mumol/kg body weight, < 30,000 Daltons) were investigated in abdominal MR imaging using a pig model (n = 24) [15].
• We synthesized a novel fluorescein isothiocyanate-labeled gadolinium-diethylenetriamine pentaacetic acid (DTPA) conjugate in which the commonly used gadolinium-DTPA complex is flanked by the nuclear localization sequences of the simian virus-40 T antigen and the acute lymphatic leukemia-1 (ALL-1) protein [16].

Biological context of Detapac

• Hydrated clearance of gadolinium-DTPA as a measurement of glomerular filtration rate [17].
• Tissue distribution and magnetic resonance spin lattice relaxation effects of gadolinium-DTPA [18].
• Comparative transmetallation kinetics and thermodynamic stability of gadolinium-DTPA bis-glucosamide and other magnetic resonance imaging contrast media [19].
• Venous blood samples were obtained 3 days after MI and MRI was performed from 2 to 7 days after MI, with determination of left ventricular function and acquisition of perfusion data after injection of gadolinium-DTPA [20].
• Mechanical delivery of aerosolized gadolinium-DTPA for pulmonary ventilation assessment in MR imaging [21].

Anatomical context of Detapac

• Gadolinium-DTPA-enhanced nuclear magnetic resonance imaging of reperfused myocardium: identification of the myocardial bed at risk [22].
• First-pass nuclear magnetic resonance imaging studies using gadolinium-DTPA in patients with coronary artery disease [23].
• We report two cases of AIDS-related polyradiculopathy in which spinal T1-weighted MRI with gadolinium-DTPA showed enhancement of the pial lining of the conus medullaris, cauda equina, and lumbar nerve roots [24].
• The intensity of gadolinium-DTPA (Gd-DTPA) enhancement was quantitated by obtaining the value for a region of interest (ROI) of the right optic nerve and the left optic nerve [25].
• Canine cerebrospinal fluid rhinorrhea, which occurs frequently in purebred beagles, was demonstrated in two dogs on magnetic resonance images after cisternal introduction of gadolinium-DTPA dimeglumine [26].

Associations of Detapac with other chemical compounds

• A contrast agent for use in magnetic resonance (MR) imaging of the liver and spleen has been designed in which gadolinium-DTPA is chemically incorporated into the lamellar phase of liposome particles [27].
• Magnetic resonance imaging of focal liver lesions. Comparison of the superparamagnetic iron oxide resovist versus gadolinium-DTPA in the same patient [28].
• Quantitative analysis of dynamic gadolinium-DTPA (diethylenetriamine pentaacetic acid) enhanced magnetic resonance imaging (MRI) is emerging as a highly sensitive tool for detecting malignant breast tissue [29].
• In vitro measurements of stability constants, octanol/water partition coefficients and relaxation times in solutions of water and human serum albumin (HSA) were performed with each new chelate and compared with gadolinium-diethylenetriamine pentaacetic acid, Gd(DTPA) [30].
• This review summarizes the physical basis of magnetic resonance (MR) imaging contrast agents, including both T1 agents, such as gadolinium-DTPA (diethylenetriaminepentaacetic acid), and T2 or T2* agents, such as superparamagnetic iron oxides [31].

Gene context of Detapac

• A correlative triad of gadolinium-DTPA MRI, EDSS, and CSF-MBP in relapsing multiple sclerosis patients treated with high-dose intravenous methylprednisolone [32].
• The aim of this study was to investigate if dynamic gadolinium-DTPA-supported magnetic resonance (MR) imaging can monitor the therapeutic effect of a fast-acting immuno-modulating drug like anti-tumour necrosis factor alpha (anti-TNF-alpha) monoclonal antibody (moab) in patients with rheumatoid arthritis (RA) [33].
• Gadolinium-DTPA-enhanced magnetic resonance imaging in intractable partial epilepsy [34].
• We performed serial monthly magnetization transfer (MT) imaging to evaluate whether MS lesions that enhance only after the injection of a triple dose (TD) of gadolinium-DTPA (Gd) have different pathologic characteristics and evolution than those that enhance after the injection of a standard dose (SD) [35].
• Gadolinium-DTPA produced a moderate (5-11%) or marked (9-19%) decrease in control and MBP-treated animals, respectively [36].

Analytical, diagnostic and therapeutic context of Detapac

• In this study we assessed the safety, efficacy and cost-effectiveness of the use of triple dose gadolinium-DTPA (Gd) in serial monthly brain MRI of patients with multiple sclerosis, such as could be selected for clinical trials [2].
• Cardiac images at rest were obtained during rapid intravenous injection of gadolinium-DTPA (0.04 mM/kg) [23].
• These results demonstrate the clinical potential of dynamic gadolinium-DTPA-enhanced NMR imaging for the assessment of coronary artery disease in patients with chest pain [23].
• In 12 patients with definite multiple sclerosis who received a total of 21 courses of high-dose (1 gram daily for 10 consecutive days) intravenous methylprednisolone, we performed MRI of the brain with and without gadolinium-DTPA before and after treatment [14].
• Magnetic resonance imaging with fat saturation after the administration of gadolinium-DTPA can detect and demarcate meningioma of the optic nerve sheath with a precision not attainable with any other current imaging technique [37].

References